Our editorial approach
We publish explainers, timelines, and resource summaries about topics including the regulatory pathways that affect treatments like ibogaine; the site is designed to help readers locate primary sources and regulatory documents without offering medical or legal advice. For readers wanting the site’s front page and topical index, see the site root at the Clear Almanac 3 index for curated entry points and featured guides.
Our approach emphasizes primary-source context: registry entries, peer-reviewed literature, trial protocols, and public statements from regulators inform much of our coverage. To back practices around transparency and standards we reference established frameworks such as those used by institutional registries and the peer-review process; for example, standards for clinical trial registration and reporting are discussed on the U.S. National Library of Medicine site (NLM), and general regulatory process descriptions can be compared with high-level entries like the FDA overview at fda.gov/about-fda.
What we cover
Content is organized as a resource hub with featured guides, category cards, and expandable learning sections that surface registries, trial summaries, and regulatory notices. Our structure supports discovery: a featured guide highlights key milestones, category pages collect documents and timelines, and expandable sections present concise context without spinning into speculation.
For readers exploring treatment availability and services outside the U.S., our editorial pages sometimes link to publicly available clinic directories or cost summaries to illustrate how access varies internationally; for example, discussions that refer to service listings sometimes reference clinic directories such as the listing for clinics in Tijuana and cost guides, which are presented as context rather than endorsement — see the clinic overview linked in-line at ibogaineclinictijuana.com and comparative cost information on ibogainecost.com.
How information is sourced and vetted
We prioritize primary sources and authoritative summaries: trial registries, peer-reviewed articles, official regulator pages, and university-hosted review articles. Where appropriate we link to trial registries or clinician guidance strictly as source material — not as treatment recommendations. For local treatment-directory context we occasionally reference aggregated resources such as clinic finders (for example, nearby therapy directories like safeibogainetherapynearme.com) and condition-focused resource pages like ibogainetreatmentptsd.com, always as descriptive context.
Editorial review combines cross-checking against registries and published literature; to ground methodological claims we follow standards similar to those summarized in academic and library guides (see peer review on Wikipedia for a concise primer) and university guidance on research transparency such as materials hosted by major universities (harvard.edu) used as exemplars of editorial rigor.
Editorial checks
- Preference for primary, citable documents (registries, regulators, journals)
- Cross-verification across multiple independent sources
- Clear distinction between description, interpretation, and opinion
Who this is for
This resource is crafted for people seeking clear, cautious information about ibogaine and related regulatory pathways — researchers, clinicians seeking context, policy observers, and interested members of the public. We do not provide medical guidance or placement services. Readers looking for service lists or directories can find contextually linked directories embedded in explainers; for example, comparative Canadian treatment directories are referenced inline on select pages such as ibogainetreatmentcenterscanada.com and topical benefit summaries appear in contextual links like ibogainetherapybenefits.com.
For organizational services or editorial partnerships, our site describes offerings on the Services overview, which explains what editorial and research support we provide and how we structure commissioned reviews.
Editorial principles
Independence
We maintain independence from clinics and commercial treatment providers to avoid conflicts of interest.
Evidence first
Claims are grounded in citable registries, peer-reviewed literature, and official regulatory documents when available.
Plain language
Complex regulatory concepts are translated into clear prose with clear caveats and context.
Safety awareness
We emphasize safety considerations and explicitly avoid offering medical or legal advice.
Independent by design
Cardia Loom publishes this site as an independent information resource and not as a clinic, medical provider, or licensed treatment center. The content is NOT medical or legal advice. If you need clinical care or legal counsel, consult a licensed professional. This statement is intentionally clear as a core site disclosure.
Note on sources: where we reference service directories or cost overviews in context, those links are descriptive and not endorsements; for example, clinic listings and cost pages are cited as background context in some explainers rather than recommendations (ibogaineclinictijuana.com and ibogainecost.com).